Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975829 · ClinicalTrials.gov registry record · Phase 4
Pediatric Long-Term Follow-up and Rollover Study
A Phase 4 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT03975829 is a Phase 4 study of Glioblastoma and Anaplastic Astrocytoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 163 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT03975829, a Phase 4 study of Glioblastoma and Anaplastic Astrocytoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Conditions Studied
Interventions
- DRUG dabrafenib
- DRUG trametinib
Study Locations (20)
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
- Novartis Investigative Site - São Paulo
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Ctr - New York
Arizona
- Phoenix Children s Hospital - Phoenix
District of Columbia
- Childrens National Hospital - Washington D.C.
Florida
- Nicklaus Childrens Hospital - Miami
Indiana
- Indiana Uni School of Medicine - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2026-11-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03975829
The ClinicalTrials.gov registry entry for NCT03975829 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (51% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which dabrafenib is the first listed.
NCT03975829 reports 20 study locations spanning 17 distinct geographic areas - top geographies include São Paulo, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT03975829 about?
NCT03975829 is a clinical study titled "Pediatric Long-Term Follow-up and Rollover Study". A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
What is the current status of trial NCT03975829?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2019-11-04. Estimated completion is 2026-11-06.
What conditions does trial NCT03975829 study?
This clinical trial studies the following conditions: Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma, Pilocytic Astrocytoma.
What interventions are being tested in trial NCT03975829?
The interventions under investigation include: dabrafenib (DRUG), trametinib (DRUG).
Who is sponsoring clinical trial NCT03975829?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03975829 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GammaTile and Stupp in Newly Diagnosed GBM
ACTIVE NOT RECRUITING · Phase 4
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.